Company / Shareholders' Equity
Vanda Pharmaceuticals Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$538.5M
FY2025
5-year range
$410.9M / $538.5M
FY2021-FY2025
Trend
+2.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has increased for 7 consecutive years, from $131M in FY2018 to $539M in FY2025.
Based on SEC 10-K filings.
$539M in FY2025 with a 5-year CAGR of +14.4%.
Improved from $505M to $539M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +5.9%
- 5-Year CAGR
- +14.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- Vanda Pharmaceuticals Inc.'s shareholders' equity has grown for 7 consecutive years.
- 5-year CAGR of +14.4%, indicating consistent growth.
- In FY2025, shareholders' equity increased 2.2% year-over-year.
- Lowest shareholders' equity in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -3.96 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $538.5M | +2.2% |
| FY2024 | $527.2M | +4.4% |
| FY2023 | $504.9M | +11.4% |
| FY2022 | $453.3M | +10.3% |
| FY2021 | $410.9M | +49.2% |
| FY2020 | $275.4M | +109.6% |
| FY2019 | $131.4M | +0.0% |
| FY2018 | $131.3M | -1.3% |
| FY2017 | $133.0M | -17.3% |
| FY2016 | $160.8M | +264.5% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026